[Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
There is increasing evidence in the literature for persistent deficiency in cell-mediated immunity (CMI) in Hodgkin's diseases during apparent remissions after discontinuation of the treatment. Patients were followed for 6 months to 2 years after all treatments were stopped. There was a high percentage (41.6) of subjects with skin anergy to seven recall antigens, a highly significant (p less than 0,0001) decrease, as compared with controls, in total and active E rosettes independently from the number of lymphocytes, and a highly significant diminution of T-lymphocyte in vitro reactivity to various doses of phyto haemagglutinine (PHA). There was no difference between the patients tested between 6 months and 1 year and those tested more than 2 years after treatment. No correlation between skin tests and active rosettes was found in this series. Finally, the CMI deficiency is some what different in patients on remission and in untreated patients.
D005260:Female; D006689:Hodgkin Disease / Q000276:immunology* / Q000628:therapy; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007111:Immunity, Cellular; D007428:Intradermal Tests; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D012075:Remission, Spontaneous; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000502:physiology; D013997:Time Factors
Déficit persistant de l'immunité cellulaire dans la maladie de Hodgkin en rémission complète.